Omalizumab for the treatment of chronic inducible urticaria in 80 patients. Exposito-Serrano V, Curto-Barredo L, Aguilera Peiro P, Gomez Armayones S, et al. Br J Dermatol 2021;184:167-168.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Exposito-Serrano V, Curto-Barredo L, Aguilera Peiro P, Gomez Armayones S, et al. Omalizumab for the treatment of chronic inducible urticaria in 80 patients. Br J Dermatol 2021;184:167-168.
PMID: 32730636